{"id":215813,"date":"2026-07-13T04:12:16","date_gmt":"2026-07-13T04:12:16","guid":{"rendered":"https:\/\/www.europesays.com\/ch-fr\/215813\/"},"modified":"2026-07-13T04:12:16","modified_gmt":"2026-07-13T04:12:16","slug":"patrick-aebischer-president-de-timeline-il-y-a-un-enorme-potentiel-parce-que-nous-vivons-plus-vieux-mais-en-mauvaise-sante","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch-fr\/215813\/","title":{"rendered":"Patrick Aebischer, pr\u00e9sident de Timeline: \u00abIl y a un \u00e9norme potentiel parce que nous vivons plus vieux, mais en mauvaise sant\u00e9\u00bb"},"content":{"rendered":"<p>N\u00e9e en 2007 sous le nom d\u2019Amazentis, Timeline ambitionne de prolonger la dur\u00e9e de vie en bonne sant\u00e9 \u00e0 l\u2019aide de ses suppl\u00e9ments alimentaires. La soci\u00e9t\u00e9 s\u2019est construite autour de recherches men\u00e9es \u00e0 l\u2019EPFL sur une mol\u00e9cule: l\u2019urolithine A. En 2016, elles mettent en \u00e9vidence son influence sur le \u00abrecyclage\u00bb des mitochondries, des composantes des cellules produisant de l\u2019\u00e9nergie, et, par extension, sur le vieillissement musculaire. La start-up d\u00e9veloppe un proc\u00e9d\u00e9 de synth\u00e8se de cette mol\u00e9cule, commercialis\u00e9e sous le nom de Mitopure.<\/p>\n<p>Apr\u00e8s plusieurs lev\u00e9es de fonds \u00e0 succ\u00e8s, dont la derni\u00e8re en 2024, Timeline a annonc\u00e9 en d\u00e9but d\u2019ann\u00e9e un partenariat avec Lanc\u00f4me, marque du groupe fran\u00e7ais L\u2019Or\u00e9al, dans le domaine des cosm\u00e9tiques. Cofondateur et pr\u00e9sident de l\u2019entreprise vaudoise, Patrick Aebischer revient pour Le Temps sur ce choix strat\u00e9gique et les projets de d\u00e9veloppement de la soci\u00e9t\u00e9.<\/p>\n","protected":false},"excerpt":{"rendered":"N\u00e9e en 2007 sous le nom d\u2019Amazentis, Timeline ambitionne de prolonger la dur\u00e9e de vie en bonne sant\u00e9&hellip;\n","protected":false},"author":2,"featured_media":215814,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4],"tags":[22,15582,2748,1226,21,174,23],"class_list":["post-215813","post","type-post","status-publish","format-standard","has-post-thumbnail","category-actualites","tag-actualites","tag-biotech","tag-economie-romande","tag-economie-suisse","tag-news","tag-premium","tag-suisse"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch_fr\/116910721943871919","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/posts\/215813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/comments?post=215813"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/posts\/215813\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/media\/215814"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/media?parent=215813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/categories?post=215813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch-fr\/wp-json\/wp\/v2\/tags?post=215813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}